Endocrinology Today—June 2, 2026

LucidQuest

7 hours ago

This week’s Endocrinology update highlights regulatory actions, clinical data advances, diabetes technology developments, AI-enabled screening initiatives, and evolving disease management approaches across endocrine care.

In Today’s Newsletter

Dive deeper

🧬 Corcept relacorilant NDA resubmission planned [1] [US • 27 May 2026]

https://ir.corcept.com/news-releases/news-release-details/corcept-resubmit-its-new-drug-application-relacorilant-treatment
Context: Corcept Therapeutics is developing relacorilant for patients with Cushing’s syndrome, also described as hypercortisolism.
Key point: Corcept plans to resubmit its NDA to FDA after additional analyses requested in a complete response letter.
Implication: May influence prescriber choice and payer reviews pending full data.

🩻 AI chest X-ray analysis for osteoporosis screening [2] [30 May 2026]

https://www.geneonline.com/ai-analysis-of-chest-x-rays-could-broaden-osteoporosis-screening-beyond-older-women/
Context: Researchers are exploring AI analysis of routine chest X-rays to detect bone loss and fracture risk.
Key point: The approach could broaden osteoporosis screening beyond older women and current high-risk groups.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🤰 Tandem Control-IQ+ cleared for pregnancy with T1D [3] [US • 29 May 2026]

https://www.breakthrought1d.org/news-and-updates/aid-approved-for-pregnancy/
Context: FDA cleared Tandem’s Control-IQ+ automated insulin delivery technology for pregnancy with type 1 diabetes.
Key point: CIRCUIT trial users spent about 3 more hours per day in the recommended pregnancy glucose range than controls.
Implication: May expand screening, initiation, and follow-up at scale.

💉 Lilly Mounjaro outperforms some GLP-1 comparators [4] [29 May 2026]

https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-mounjaro-tops-other-glp-1s-some-type-2-diabetes-patients-2026-05-29/
Context: SURPASS-EARLY enrolled nearly 800 adults with type 2 diabetes diagnosed within the past four years.
Key point: Mounjaro (Eli Lilly; tirzepatide) improved HbA1c, weight, and waist circumference more than control treatments.
Implication: May influence prescriber choice and payer reviews pending full data.

⚠️ Insulet Omnipod Pods correction for under-delivery risk [5] [US, international • 26 May 2026]

https://www.businesswire.com/news/home/20260526676657/en/Insulet-Initiates-Voluntary-Medical-Device-Correction-for-Certain-Omnipod-Pods-in-the-U.S.-and-Affected-International-Markets
Context: Insulet identified a manufacturing issue affecting specific lots of Omnipod 5, Omnipod DASH, and Omnipod Eros Pods.
Key point: The issue could cause insulin under-delivery, high glucose, and in severe cases diabetic ketoacidosis.
Implication: Introduces competition that may affect pricing and formulary access.

🔗 Tidepool launches diabetes data integration in Epic Showroom [6] [US • 27 May 2026]

https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care
Context: Tidepool+ Direct Connect is built on SMART on FHIR and is now available through Epic Showroom.
Key point: Clinicians can launch Tidepool+ inside Epic and review interactive diabetes device data during visits.
Implication: May expand screening, initiation, and follow-up at scale.

🌬️ Afrezza approved for pediatric diabetes mealtime insulin [7] [US • 29 May 2026]

https://www.contemporarypediatrics.com/view/fda-approves-inhaled-insulin-afrezza-for-children-and-adolescents-with-diabetes
Context: FDA approved Afrezza (MannKind; insulin human inhalation powder) for patients aged 6 years and older with diabetes.
Key point: INHALE-1 showed noninferiority to injected rapid-acting insulin analogs for HbA1c change over 26 weeks.
Implication: May influence prescriber choice and payer reviews pending full data.

🌏 Fitness Sci-Tec targets India with AI diabetes platform [8] [New Zealand, India • 25 May 2026]

https://www.thepost.co.nz/business/361009437/auckland-ai-powered-diabetes-platform-sets-sights-india
Context: Auckland-based Fitness Sci-Tec operates a diabetes prevention and management platform with Health NZ support.
Key point: The company is preparing expansion into India while running a South Auckland diabetes pilot through 30 Jun 2026.
Implication: Signals pipeline investment and modality expansion.

Why It Matters

Diabetes technology is moving deeper into care workflows, pregnancy management, and pediatric insulin delivery.
Regulatory actions this week span approvals, planned resubmissions, and device corrections, creating near-term watchpoints for clinicians.
AI-enabled screening and disease-management tools continue to extend beyond traditional hospital or specialist settings.
GLP-1 competition remains clinically important, especially as earlier use in type 2 diabetes gains more trial attention.

📚 View the full Endocrinology archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Endocrinology news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is Corcept seeking for relacorilant?

Corcept plans to resubmit an FDA NDA for relacorilant as a treatment for patients with Cushing’s syndrome. The company says FDA expects a PDUFA date six months after resubmission. [1]

What makes Tandem Control-IQ+ notable for pregnancy with type 1 diabetes?

Tandem Control-IQ+ is described as the first automated insulin delivery technology cleared in the US for pregnancy with type 1 diabetes. The CIRCUIT trial reported about 3 more hours per day in pregnancy glucose range. [3]

What did SURPASS-EARLY report for Lilly’s Mounjaro?

SURPASS-EARLY reported that Mounjaro (tirzepatide) produced greater improvements in HbA1c, weight, and waist circumference than control treatments in recently diagnosed type 2 diabetes after metformin was inadequate. [4]

Which Insulet products are affected by the correction?

The correction covers specific lots of Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System (Omnipod Eros) Pods. Insulet said affected lots may cause insulin under-delivery. [5]

What changed for Afrezza?

FDA approved Afrezza inhaled insulin for patients aged 6 years and older with diabetes. The approval makes it the first rapid-acting inhaled insulin available for pediatric patients requiring mealtime insulin. [7]

What is Fitness Sci-Tec planning in India?

Fitness Sci-Tec, an Auckland AI-powered diabetes platform, is preparing to expand into India. The source says the move is expected in coming months, while the New Zealand pilot runs through 30 Jun 2026. [8]

Entities / Keywords

Corcept Therapeutics, relacorilant, Cushing’s syndrome, hypercortisolism, FDA NDA, PDUFA
AI chest X-ray analysis, osteoporosis screening, bone loss, fracture risk
Tandem Diabetes Care, Control-IQ+, automated insulin delivery, AID, type 1 diabetes, pregnancy, CIRCUIT trial
Eli Lilly, Mounjaro, tirzepatide, GLP-1, type 2 diabetes, SURPASS-EARLY, HbA1c
Insulet, Omnipod 5, Omnipod DASH, Omnipod Eros, insulin under-delivery, diabetic ketoacidosis
Tidepool, Tidepool+ Direct Connect, Epic Showroom, SMART on FHIR, diabetes device data
MannKind, Afrezza, insulin human inhalation powder, pediatric diabetes, INHALE-1
Fitness Sci-Tec, Health NZ, Pacific Diabetes Northern Region, diabetes prevention, India expansion